LAVA Therapeutics NV Revenue
LAVA Therapeutics NV reported Revenue of $11.98 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-06
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $4.99M.
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00.
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $0.00.
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $6.99M.
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for fiscal 2024 was $11.98M, a 77.01% increase from fiscal 2023.
- LAVA Therapeutics NV revenue from contract with customer, excluding assessed tax for fiscal 2023 was $6.77M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $4.99M derived: sum of 2 quarters · filed 2025-11-06 | $4.99M derived: sum of 3 quarters · filed 2025-11-06 | $11.98M 10-K · filed 2025-03-28 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $6.99M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $6.99M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $6.99M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $6.77M 10-K · filed 2025-03-28 |